• Publications
  • Influence
Chimeric antigen receptor T cells for sustained remissions in leukemia.
Chimeric antigen receptor-modified T-cell therapy against CD19 was effective in treating relapsed and refractory ALL and was associated with a high remission rate, even among patients for whom stem-cell transplantation had failed, and durable remissions up to 24 months were observed. Expand
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
The in vivo expansion of theCAR T cells correlated with clinical responses, and the CAR T cells persisted and remained functional beyond 4 years in the first two patients achieving CR, suggesting that disease eradication may be possible in some patients with advanced CLL. Expand
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.
The goal is to provide a uniform consensus grading system for CRS and neurotoxicity associated with immune effector cell therapies, for use across clinical trials and in the postapproval clinical setting. Expand
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.
The first models that can accurately predict which patients are likely to develop severe CRS before they become critically ill are developed, which improves understanding of CRS biology and may guide future cytokine-directed therapy. Expand
Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia.
  • N. Frey, D. Porter
  • Medicine
  • Hematology. American Society of Hematology…
  • 2 December 2016
Collaborative efforts are underway to harmonize the definition and grading system of CRS to allow for better interpretation of toxicities across trials and allow for informed management algorithms. Expand
Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia
Clinicians should be aware of expanding use of this breakthrough therapy and implications for critical care units in cancer centers and the timing, severity, and intensive care management of cytokine release syndrome after chimeric antigen receptor–modified T cell therapy. Expand
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
A mechanistically relevant population of CD27+PD-1–CD8+ CAR T cells expressing high levels of the IL-6 receptor predicts therapeutic response and is responsible for tumor control, and new features of CAR T cell biology are uncovered. Expand
Primary lymphomas of the cervix and uterus: The University of Pennsylvania's experience and a review of the literature
Based on the case series and a review of available literature, primary lymphomas of the uterus or cervix are rare and require an individualized approach to treatment and patients with limited stage disease should be treated with localized and systemic therapy to optimize chances of cure. Expand
Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia.
The results described here are the first detailed formal presentation of cellular kinetics across 2 diseases and highlight the importance of the application of in vivo cellular kinetic analyses to characterize clinical efficacy and CRS severity associated with CTL019 therapy. Expand
Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
Clinical experience with the anti-CD19 CAR T cell therapy tisagenlecleucel at the University of Pennsylvania was used to develop the Penn grading scale for Cytokine release syndrome (CRS), which provides reproducible CRS grading that can be useful to guide therapy and applied across clinical trials and treatment platforms. Expand